Literature DB >> 22493387

A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples.

Giuseppe Pelosi1, Flavia Melotti, Alberto Cavazza, Giulio Rossi, Patrick Maisonneuve, Paolo Graziano, Mattia Barbareschi, Yukio Nakatani, Mauro Papotti.   

Abstract

BACKGROUND: As pulmonary sarcomatoid carcinomas (PSCs) are life-threatening tumors, an improvement in their recognition in small-sized tumor samples is clinically warranted.
MATERIALS AND METHODS: Preoperative biopsy samples and paired surgical specimens from 20 pleomorphic carcinomas, two pulmonary blastomas and one carcinosarcoma (training set) were studied for vimentin immunohistochemistry. A modified vimentin histologic score (M-VHS) was devised by multiplying three independently assessed parameters, i.e. the percentage of positive cells (from 0 to 5+, by quintiles), the intensity of immunostaining (low=1 vs. strong=2) and the distribution pattern within the cytoplasm (partial=1 vs. diffuse=2), so ranging from 0 to 20. Forty-eight consecutive and independent cases of non-small cell lung carcinoma (NSCLC), including two additional cases of PSC, were used as control groups (validation set).
RESULTS: No differences in M-VHS were found between biopsies and surgical specimens of PSC, thus confirming the occurrence of stable epithelial mesenchymal transition (EMT) and hence the specific diagnosis of PSC. All types of PSC shared the same M-VHS. The M-VHS of 46 conventional NSCLC was by far lower (p<0.0001), whereas two additional cases of PSC showed the same results as the training set. Poorly differentiated NSCLC with marked pleomorphism but not stable EMT did not exhibit significantly increased M-VHS values.
CONCLUSION: M-VHS helped in morphological analysis to render more definite diagnoses on small biopsies of PSC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493387

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections.

Authors:  Giuseppe Pelosi; Federica Perrone; Elena Tamborini; Alessandra Fabbri; Maria Adele Testi; Adele Busico; Giulio Settanni; Benedetta Picciani; Enrica Bovio; Angelica Sonzogni; Barbara Valeri; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-01-27       Impact factor: 4.064

2.  Pulmonary pleomorphic carcinoma with multiple metastases to the right posterior knee complicated by paraneoplastic hypercalcemia.

Authors:  Peng-Fei Li; Cheng-Hsiang Lo; Shan-Han Yang; Ping-Ying Chung; Ching-Liang Ho
Journal:  Oncol Lett       Date:  2013-12-09       Impact factor: 2.967

3.  Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer.

Authors:  Nicholas Willumsen; Cecilie L Bager; Diana J Leeming; Victoria Smith; Claus Christiansen; Morten A Karsdal; David Dornan; Anne-Christine Bay-Jensen
Journal:  Cancer Med       Date:  2014-07-18       Impact factor: 4.452

4.  Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma.

Authors:  Kazuya Takeda; Haruo Matsushita; Masaki Kubozono; Takaya Tanabe; Yojiro Ishikawa; Takaya Yamamoto; Maiko Kozumi; Noriyoshi Takahashi; Yu Katagiri; Shun Tasaka; Katsuya Fukui; Ken Takeda; Fumiyoshi Fujishima; Masakazu Ichinose; Keiichi Jingu
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

5.  Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness.

Authors:  Massimo Moro; Giulia Bertolini; Roberto Caserini; Cristina Borzi; Mattia Boeri; Alessandra Fabbri; Giorgia Leone; Patrizia Gasparini; Carlotta Galeone; Giuseppe Pelosi; Luca Roz; Gabriella Sozzi; Ugo Pastorino
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

6.  Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders.

Authors:  Signe Holm Nielsen; Nicholas Willumsen; Diana Julie Leeming; Samuel Joseph Daniels; Susanne Brix; Morten Asser Karsdal; Federica Genovese; Mette Juul Nielsen
Journal:  Transl Oncol       Date:  2018-11-30       Impact factor: 4.243

7.  Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases.

Authors:  Si-Yuan Huang; Shu-Jing Shen; Xing-Ya Li
Journal:  World J Surg Oncol       Date:  2013-10-02       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.